Germline mutations among Polish patients with acute myeloid leukemia

• Published in: Hereditary cancer in clinical practice Vol. 19; no. 1; pp. 1 - 42
• Main Authors: BÄk, Aneta, Skonieczka, Katarzyna, JaÅkowiec, Anna, Junkiert-Czarnecka, Anna, Heise, Marta, Pilarska-Deltow, Maria, Potoczek, StanisÅaw, Czyżewska, Maria, Haus, Olga
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 12.10.2021; BioMed Central; BMC
• Subjects: Acute myeloid leukemia; Age; AML; Analysis; Bone marrow; Cancer; CEBPA; CEBPA gene; DDX41; Dehydrogenases; DNA methylation; DNA sequencing; ETV6; Family medical history; Gene expression; Gene mutations; Genetic aspects; Genetic counseling; Genomes; germline mutations; Hematopoietic stem cells; Leukemia; Mutation; Myeloid leukemia; Proteins; Statistical analysis; Stem cell transplantation; Telomerase; Transcription factors; Transplantation; Poland
• ISSN: 1897-4287; 1731-2302; 1897-4287
• DOI: 10.1186/s13053-021-00200-2

Background A small but important proportion of patients (4-10 %) with AML have germline mutations. They can cause the development of AML at an earlier age, confer a higher risk of relapse or predispose to secondary leukemias, including therapy-related leukemias. The analysis of germline mutations in a patient and his/her family is also critical for the selection of suitable family donors if the patient is a candidate for hematopoietic stem cell transplantation (HSCT). Methods 103 unrelated consecutive patients with de novo AML were enrolled in the study. Control group consisted of 103 persons from the general population. We performed NGS sequencing of bone marrow cells and buccal swabs DNA of six genes: CEBPA, DDX41, ETV6, TERT, GATA2, and IDH2 to detect germline pathogenic mutations. Results In the investigated group, 49 variants were detected in six genes. 26 of them were somatic and 23 germline. Germline variants were detected in all six tested genes. Eight pathogenic germline mutations were detected in 7 AML patients, in three genes: CEBPA, ETV6, and IDH2. One patient had two pathogenic germinal mutations, one in ETV6 and one in CEBPA gene. We identified one novel pathogenic germline mutation in CEBPA gene. The difference in frequency of all pathogenic germline mutations between the tested (7.77 %) and control groups (0.97 %) was statistically significant (p = 0.046). In the tested group, the median age at AML diagnosis was 11 years lower in patients with pathogenic germline mutations than in patients without them (p = 0.028). Conclusions We showed higher frequency of CEBPA, ETV6, and IDH2 germline mutations in AML patients than in control group, which confirms the role of these mutations in the development of AML. We also showed that the median age at the onset of AML in patients with pathogenic germline mutations is significantly lower than in patients without them. Keywords: Acute myeloid leukemia, AML, germline mutations, CEBPA, DDX41, ETV6, TERT, GATA2, IDH2